A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease

Blood

Volumn 95, Issue 12, 2000, Pages 3693-3701

  Van Oosterhout, Ypke V J M ^a   Van Emst, Liesbeth ^b   Schattenberg, Anton V M B ^b   Tax, Wil J M ^b   Ruiter, Dirk J ^b   Spits, Hergen ^b   Nagengast, Okke M ^b   Masereeuw, Roos ^b   Evers, Sabine ^b   De Witte, Theo ^b   Preijers, Frank W M B ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CREATINE KINASE; IMMUNOTOXIN; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD7; RICIN A; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; EDEMA; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034660190     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3693.012k22_3693_3701     Document Type: Article

References (48)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
2. Ferrara JL, Deeg HJ. Graft-versus-host disease [see comments]. N Engl J Med. 1991;324:667-674.
3. Antin JH, Ferrara JL: Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80: 2964-2968.
4. Keman NA, Byers V, Scannon PJ, et al. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA. 1988;259:3154-3157.
5. Byers VS, Henslee PJ, Kernan NA, et al. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990;75:1426-1432.
6. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation. 1994;58:437-442.
7. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996; 88:824-830.
8. Spits H, Keizer G, Borst J, Terhorst C, Hekman A, de Vries JE. Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines. Hybridoma. 1983;2:423-437.
9. Tax WJ, Greaves MF, Willems HM, Leeuwenberg HF, Capel PJ, Koene RA, WT1: a monoclonal antibody reactive with T-ALL but not with other leukemias. Hamatol Bluttransfus. 1983;28:139-141.
10. Tax WJ, Tidman N, Janossy G, et al. Monoclonal antibody (WT 1) directed against a T cell surface glycoprotein: characteristics and immunosuppressive activity. Clin Exp Immunol. 1984;55:427-436.
11. Ghetie V, Thorpe P, Ghetie MA, Knowles P, Uhr JW, Vitetta ES. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods. 1991;142:223-230.
12. Burrows SR, Misko IS, Sculley TB, Schmidt C, Moss DJ. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol. 1990;64:3974-3976.
13. Amlot PL, Stone MJ, Cunningham D. et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624-2633.
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
15. Preijers FW, Tax WJ, Wessels JM, Capel PJ, De Witte T, Haanen C. Different susceptibilities of normal T cells and T cell lines to immunotoxins. Scand J Immunol. 1988;27:533-540.
16. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today. 1993;14:338-339
17. Rhoades JL, Cibull ML, Thompson JS, et al. Role of natural killer cells in the pathogenesis of human acute graft-versus-host disease. Transplantation. 1993;56:113-120.
18. Hill GR, Krenger W, Ferrara JL. The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther. 1997;3:257-266.
19. Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma. 1997;26:287-298.
20. Stone MJ, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA. in patients with B-cell lymphoma. Blood. 1996;88: 1188-1197.
21. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052-4058.
22. Vallera DA, Ash RC, Zanjani ED, et al. Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science. 1983;222:512-515.
23. Uckun FM, Azemove SM, Myers DE, Vallera DA. Anti-CD2 (T, p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation. Leuk Res. 1986;10:145-153.
24. Katz FE, Janossy G, Cumber A, et al. Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Br J Haematol. 1987;67:407-411.
25. Crews JR, Maier LA, Yu YH, et al. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int J Cancer. 1992;51:772-779.
26. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-GD19 antibody or an anti-CD19 immunotoxin. Blood. 1992;80:2315-2320.
27. Engert A, Gottstein C, Bohlen H, et al. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int J Cancer. 1995;63:304-309.
28. Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 1997;57:4824-4829.
29. Hollrop S, Rijke-Schilder GP, Koene RA, Tax WJ. A polymorphic Fc receptor for mouse IgG2b on human B cells and monocytes. Immunology. 1991;74:613-620.
30. Frenken LA, Koene RA, Tax WJ. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CDS-induced T cell proliferation. Transplantation. 1991;51:881-887.
31. Conry RM, Khazaeli MB, Saleh MN, et al. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol. 1995;18: 231-241.
32. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85:3457-3465.
33. Senderowicz AM, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 1997; 126:882-885.
34. Engert A. Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 1997;89:403-410.
35. Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood. 1991;77:182-194.
36. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol. 1999;163:6072-6077.
37. Greco B, Bielory L, Stephany D, et al. Antithymocyte globulin reacts with many normal human cell types. Blood. 1983;62:1047-1054.
38. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS. Biological and immunological characterization of ATG and ALG. Blood, 1986;68:712-719.
39. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation. 1994;57:685-694.
40. Bell L, Girardin C, Sharma A, Goodyer P, Mazer B. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion. Transplant Proc. 1997;29:65-95.
41. Muller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies [see comments). Transplantation. 1997;64:1432-1437.
42. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol. 1993;150:4338-4345.
43. Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992;140:197-205.
44. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol. 1982;12: 979-982.
45. Bertram JH, Gill PS, Levine AM, et al. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacoKinetic, and immunologic correlation. Blood. 1986;68:752-761.
46. Parlevliet KJ, ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT. In vivo effects of IgA and IgG2a anti-CDG isotype switch variants. J Clin Invest. 1994;93:2519-2525.
47. Anasetti C, Martin PJ, Storb R, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation. 1992;54:844-851.
48. Land W, Hillebrand G, Illner WD, et al. First clinical experience with a new TCR/CD3-monoclonal antibody (BMA 031) in kidney transplant patients [letter]. Transpl Int. 1988;1:116-117.